3 recruiting, 2 not yet recruiting, 1 enrolling by invitation, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow High Grade B Cell Lymphoma: new trials by email Literature Review of High Grade B Cell Lymphoma trials Research Report on High Grade B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Prospective ctDNA Testing in Large B-Cell Lymphoma Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such as R-CHOP, Pola-R-CHP, or DA-EPOCH-R. - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Recruiting | Peking University People's Hospital | 100 | 2026-10-15 | 2026-10-16 | |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy Chimeric Antigen Receptor T-cells (CAR-T) therapy - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-05-01 | 2026-03-13 | |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | Enrolling by invitation | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2026-02-26 | 2026-06-11 | |
| A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma Glofitamab, Polatuzumab, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 42 | 2025-01-16 | 2026-07-22 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 |
Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Follicular (3) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (5) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1)
Rituximab (2) · Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · Cyclophosphamide (1) · Doxorubicin (1) · Immunotherapy, Adoptive (1) · Sirolimus (1) · Therapeutics (1) · glofitamab (1) · obinutuzumab (1) · polatuzumab vedotin (1)
AbelZeta Inc. (1) · Fondazione Italiana Linfomi - ETS (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Peking University People's Hospital (1) · Umoja Biopharma (1) · University of Arizona (1)
United States (4) · China (1) · Italy (1) · Taiwan (1)
Daniel O. Persky, MD (1) · Jin Lu (1) · Luca Castagna (1) · Luke Walker, MD (1) · Pallawi Torka, MD (1) · Yihong Yao, PhD (1)